In a four-week pilot, low-dose rapamycin lined up with higher brain blood flow in 9 APOE4 carriers and not in 14 non-carriers

What the research found

ScienceDaily published this account on 5 November 2026. The feed clock, 20:11 Eastern, is 6 November in Bangkok. The paper it describes, DOI 10.1177/0271678X261490342, is a 2026 report in the Journal of Cerebral Blood Flow & Metabolism from Chetan Aware, Ai-Ling Lin, and colleagues. It is a single-arm pilot, ClinicalTrials.gov NCT05386914. Cognitively healthy adults ages 45 to 65 took rapamycin (sirolimus) 1 mg a day for 4 weeks. Twenty-three people finished: 9 APOE4 carriers and 14 non-carriers. Brain blood flow rose in the carriers, by more than 15 percent in several regions, and did not change clearly in the non-carriers. The ScienceDaily account says women showed the strongest change. The abstract used here does not give that split as a number. There was no placebo group. The paper was not a new 6 November trial. Rapamycin here is a prescribed transplant and specialty drug, used off label in healthy adults. It is not a supplement and not a prevention program for Alzheimer's disease. DOI 10.1177/0271678X261490342. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at ScienceDaily